This year’s Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting 2016, held April 19 to 22 in San Francisco, will feature several sessions of important to managed care professionals. Here are our top 10 recommendations.
CMS regulation will lead to major changes in Medicaid managed care programs; changes that focus on quality improvements, increased transparency and accountability, and strengthened state and federal oversight.
Some experts argue that prescription drug monitoring programs can be a game changer when it comes to curbing prescription abuse and misuse. Here are 11 states that stand out for their PDMPs (or lack thereof).
Here is an analysis of trending technologies and how they affect patient satisfaction.
A number of traditional brand-name pharmaceuticals have lost, or will lose, patent protection this year. What does this mean over the longer-term for controlling costs?
PCSK9 inhibitor benefits patients with statin intolerance
Don’t let these common misconceptions stop you from this high-impact, low-cost way to engage with patients.
Type 2 diabetes medicines containing saxagliptin and alogliptin may increase the risk of heart failure, particularly in patients who already have heart or kidney disease, according to FDA’s new Drug Safety Communication.
Telemedicine could improve diabetic patient outcomes, expand access, and provide better economic value for patients. Find out how.
Soon after FDA expanded access to the “abortion pill” or mifepristone (Mifeprex, Danco Laboratories), some states may be combating the decision.
A recent Supreme Court decision shines the spotlight on the healthcare price transparency debate.
FDA recently approved reslizumab (Cinqair, Teva Pharmaceuticals), an injectable used with other asthma medicines for the maintenance treatment of severe asthma. Here are the top 5 facts to know about Cinqair.
Consequences range from cardiovascular disease to renal disease
The approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.
Here are some of the innovative approaches payers and providers are taking to quell the diabetes epidemic, and curb the costs associated with it.
As patients look to make more informed decisions about healthcare services, payers can leverage comparative analytics to deliver greater price transparency
There is so much data available at all levels of healthcare, and technology and public support is on the cusp of a breakthrough in using this information for widespread improvements.
FDA recently approved the first generic version of Nasonex nasal spray (mometasone furoate monohydrate, Apotex Corp).
Here are three questions payers must ask to determine providers’ readiness to engage in risk-based reimbursement.
A successful YMCA diabetes program has prompted the Obama administration to expand Medicare to cover programs to prevent diabetes among those at high risk of developing the disease.
Diabetes prevention program found to improve quality and reduces healthcare costs. It will now be covered by Medicare in 2017.
The sheer volume of diabetes patients has made it a big driver of medication spending. Here are some important formulary considerations.
FDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults.
FDA approved ixekizumab (Taltz, Eli Lilly and Co.) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
State and federal regulations, health information breaches, create a minefield of issues
Industry insiders believe that the Anthem lawsuit against Express Scripts over drug pricing may provide some clues into this complex situation.
Concerns among stakeholders may call for EHR system revamping
An in-depth look at the effects of PDMPs, which are electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients.
FDA this week approved obiltoxaximab injection, (Anthim, Elusys Therapeutics), to treat inhalational anthrax.
FDA issued a draft guidance to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF), while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug.